L. Bailey

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

John Sampson, Allan H Friedman, A. Friedman, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma

A. Friedman, D. Bigner, H. Friedman, 2011, Clinical Cancer Research.

Bevacizumab and daily temozolomide for recurrent glioblastoma

H. Friedman, D. Reardon, A. Desjardins, 2012, Cancer.

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

A. Friedman, D. Bigner, J. Herndon, 2008, Clinical Cancer Research.

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

A. Friedman, H. Friedman, D. Reardon, 2012, International journal of radiation oncology, biology, physics.

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

E. Lipp, H. Friedman, D. Reardon, 2013, Cancer medicine.

Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM).

H. Friedman, D. Reardon, J. Kirkpatrick, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM).

H. Friedman, D. Reardon, J. Kirkpatrick, 2010 .

Bevacizumab and daily temozolomide for recurrent glioblastoma

H. Friedman, D. Reardon, A. Desjardins, 2012, Cancer.